Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54
Volume 54, Issue -, Pages 205-226Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-011613-140002
Keywords
vascular immunotargeting; intracellular delivery; liposomes; polymeric nanocarriers; endothelium; cell adhesion molecules
Categories
Funding
- NHLBI NIH HHS [R01 HL073940, R01 HL087036, T32 HL007439] Funding Source: Medline
Ask authors/readers for more resources
There is a need for improved treatment of acute vascular inflammation in conditions such as ischemia-reperfusion injury, acute lung injury, sepsis, and stroke. The vascular endothelium represents an important therapeutic target in these conditions. Furthermore, some anti-inflammatory agents (AIAs) (e.g., biotherapeutics) require precise delivery into subcellular compartments. In theory, optimized delivery to the desired site of action may improve the effects and enable new mechanisms of action of these AIAs. Diverse nanocarriers (NCs) and strategies for targeting them to endothelial cells have been designed and explored for this purpose. Studies in animal models suggest that delivery of AIAs using NCs may provide potent and specific molecular interventions in inflammatory pathways. However, the industrial development and clinical translation of complex NC-AIA formulations are challenging. Rigorous analysis of therapeutic/side effect and benefit/cost ratios is necessary to identify and optimize the approaches that may find clinical utility in the management of acute inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available